The Ministry of Health of the Russian Federation has registered an amendment to the package insert on the grounds of the Smooth Drug Development clinical trial – the medicine is approved for the use by children aged 3 and above.

This clinical trial was a prospective multicenter double-blind, placebo controlled, comparative randomized parallel-group study and was conducted in accordance with GCP. The clinical trial involved 130 patients aged 3 to 14, diagnosed with URI or flu, and was carried out in 6 Russian clinical centers experienced in treating children for URI.

Smooth Drug Development provides a full range of clinical trial services not only in the Russian Federation, but also in the Republic of Belarus, the Republic of Kazakhstan, Germany, and the Baltic States. Contact us to learn more: bd@smoothdd.com